News
Kymera Therapeutics Inc (KYMR) extends cash runway into 2028, bolstered by key partnerships with Gilead and Sanofi, despite ...
Gilead Sciences said on Thursday it has appointed Sanofi's Dietmar Berger as its chief medical officer, replacing incumbent Merdad Parsey, who is preparing to leave early next year.
Q2 2025 Management View CEO Nello Mainolfi outlined major progress in 2025, declaring “the updates we've shared in the first ...
August 16, 2025 10:25 am - Industry revenue for Necitumumab is estimated to rise to $1249.4 million by 2035 from $612.2 million of 2024. The revenue ...
5d
TipRanks on MSNKymera Therapeutics’ Earnings Call: Optimism and Strategic Progress
Kymera Therapeutics, Inc. (($KYMR)) has held its Q2 earnings call. Read on for the main highlights of the call. Kymera Therapeutics’ recent ...
Nurix Therapeutics Reports Positive Clinical Data for Bexobrutideg and Advances Collaborations with Sanofi and Gilead, Highlighting Financial Growth July 09, 2025 — 04:14 pm EDT ...
Gilead Sciences, Bristol Myers, Merck, AbbVie and Sanofi are all slated to release their quarterly results later this week. Let's see how these pharma bigwigs are likely to have performed in the ...
Kymera Therapeutics may have signed a $750 million deal with Gilead, but the Watertown biotech also suffered a setback in its partnership with Sanofi and announced a $250 million secondary offering.
Gilead Sciences named former Sanofi executive Dietmar Berger as chief medical officer, effective Jan. 2, succeeding Merdad Parsey. Berger had held the same role at Sanofi, where he was also global ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results